On the stock market since 1989, it operates in the world of money and finance. Now — the numbers.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 10 buys and 1 sell. Management buying with its own money is usually read as a good sign.
It pays out $0.43 per share each year — regular cash for whoever holds the stock.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, XPRTX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: XPRTX is a high-risk stock — not yet profitable, and its future rides on its product catching on.